Controlled Anti-platelet medical therapy based on rapid CYP2C19 gene evaluation in Acute myocardial infarctio

Not Applicable

• Conditions: Acute myocardial infarction

• Registration Number: JPRN-UMIN000008151
• Lead Sponsor: Graduate School of Medical Sciences, Kumamoto University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2012-06-12
• Study Completion: 2017-03-27
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

Not provided

Exclusion Criteria

We exclude patients with deep vein thrombosis, cerebral infarction, atrial fibrillation, collagen disease ,disseminated intravascular coagulation, sepsis, severe infection and malignant diseases. We exclude patients who were treated with warfarin, steroids, thrombolytic agents, ticlopidine, sarpogrelate or cilostazol. We exclude patients with severe liver or renal dysfunction. We exclude patients who need mechanical cardio-plumonary supports such as intraaortic balloon pumping(IABP) or percutaneous cardiopulmonary support(PCPS).

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
1.The frequency of CYP2C19 *2, *3, and *17 polymorphism in acute myocardial infarction. 2.Difference of several change in the residual platelet aggregation and the biomarkers for blood coagulation and cardiac biomarkers.

Secondary Outcome Measures

Name	Time	Method
Composite cardiovascular events(cardiac death, fatal and non fatal stroke, non-fatal myocardial infarction, hospitalization for cardiovascular event, percutaneous coronary intervention or coronary artery bypass graft, hospitalization for heart failure, deep vein thrombosis, pulmonary thromboembolism, hospitalization for peripheral arterial disease, hemorrhagic complication)